Drug manufacturer Venus Remedies today said its research product 'Mebatic', useful in treatment of waterborne diseases, has got sales and manufacturing approvals from the Drugs Controller General of India (DCGI).
The company has got permission from DCGI for marketing and manufacturing of Mebatic, Venus said in a statement to the Bombay Stock Exchange (BSE).
"This product is intended to be used in infusion form as one of the best solutions for treatment of problems associated with waterborne bacterial/plasmodial pathogens in humans," the company said.
Shares of Venus Remedies surged over 6 per cent and were trading at Rs 294 in the afternoon trade on the BSE.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app